Metal polyphenol network coated calcium peroxide nanoparticles as well as preparation method and application thereof
By preparing metal polyphenol networks to encapsulate calcium peroxide nanoparticles, combining chemokinetics and chemotherapy, the problems of existing tumor treatment methods to complexity and multidrug resistance are solved, and more efficient tumor treatment effects are achieved, especially It has excellent anti-tumor effects in breast cancer.
Patent Information
- Application Number
- CN202411180925.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-27
AI Technical Summary
The existing tumor treatment methods are not effective in tumor treatment with complexity and multidrug resistance. It is difficult for a single treatment strategy to achieve satisfactory results. Treatment strategies with different mechanisms and targets are needed to improve the efficacy.
The metal polyphenol network is used to wrap calcium peroxide nanoparticles, and drug-loaded calcium peroxide nanoparticles are prepared through chelation, dehydration and condensation and coordination complexation reactions to form a metal polyphenol network wrapped around the surface of the nanoparticles to protect calcium peroxide. Release metal ions catalyze hydrogen peroxide in an acidic environment, kill tumor cells, and activate calcium overload to alleviate hypoxic microenvironment.
A better tumor treatment effect was achieved, and the anti-tumor efficacy was significantly improved through the combined treatment of chemokinetics and chemotherapy, especially with excellent effects on breast cancer.
Smart Images

Figure CN119033957A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of tumor treatment, and in particular to metal polyphenol network-wrapped calcium peroxide nanoparticles, and a preparation method and application thereof. Background Art
[0002] At present, although we have made significant progress in our understanding of tumorigenesis and cancer treatment, cancer deaths still account for 30% of global deaths due to tumor heterogeneity and multidrug resistance. Surgery, radiotherapy and chemotherapy have always been the three conventional methods for cancer treatment, but the therapeutic effect of traditional treatments on cancer is still unsatisfactory. New treatment strategies such as calcium overload, chemodynamic therapy, immunotherapy, photothermal therapy and photodynamic therapy can provide more ideas for the treatment of cancer. However, due to the complexity of tumors, the use of a single new treatment strategy often has limitations and cannot achieve good therapeutic effects. Therefore, the combined application of treatment strategies with different mechanisms and different targets has become an important means to improve the efficacy.
[0003] The prior art, such as the patent with publication number CN113952361A, uses Prussian blue and calcium peroxide to form a compound to improve the therapeutic effect on tumors. However, its tumor therapeutic effect is still expected to be further improved. Summary of the invention
[0004] The purpose of the present invention is to provide a metal polyphenol network-encapsulated calcium peroxide nanoparticle and a preparation method and application thereof. The metal polyphenol network-encapsulated calcium peroxide nanoparticle prepared by the present invention has a better tumor treatment effect.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides a method for preparing metal polyphenol network-encapsulated calcium peroxide nanoparticles, comprising the following steps:
[0007] (1) mixing calcium peroxide nanoparticles, a drug, and a first solvent and performing a chelating reaction to obtain drug-loaded calcium peroxide nanoparticles;
[0008] (2) mixing the polymer solution and the polyphenol solution and performing a dehydration condensation reaction to obtain a polymer-modified polyphenol solution;
[0009] (3) mixing the drug-loaded calcium peroxide nanoparticles obtained in step (1) with a second solvent, the polymer-modified polyphenol solution obtained in step (2) and a metal salt solution, and performing a coordination complex reaction to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles;
[0010] There is no chronological order for steps (1) and (2).
[0011] Preferably, in step (1), the mass ratio of calcium peroxide nanoparticles to the drug is (10-55):1.
[0012] Preferably, the temperature of the chelation reaction in step (1) is 4 to 40° C., and the time of the chelation reaction is 1 to 48 hours.
[0013] Preferably, the mass ratio of the polymer in the polymer solution in step (2) to the polyphenol in the polyphenol solution is (1-3):1.
[0014] Preferably, the temperature of the dehydration condensation reaction in step (2) is 4 to 40° C., and the time of the dehydration condensation reaction is 1 to 48 hours.
[0015] Preferably, the molar ratio of the polyphenols in the polyphenol solution of step (2) to the metal ions in the metal salt solution of step (3) is (0.5-10):1.
[0016] Preferably, the molar ratio of calcium peroxide in the drug-loaded calcium peroxide nanoparticles in step (3) to metal ions in the metal salt solution is (20-50):1.
[0017] Preferably, the temperature of the coordination complex reaction in step (3) is 4 to 40° C., and the time of the coordination complex reaction is 1 to 48 hours.
[0018] The present invention provides metal polyphenol network-wrapped calcium peroxide nanoparticles prepared by the preparation method described in the above technical scheme, comprising drug-loaded calcium peroxide nanoparticles and metal polyphenol networks wrapped on the surfaces of the drug-loaded calcium peroxide nanoparticles.
[0019] The present invention also provides the use of the metal polyphenol network-encapsulated calcium peroxide nanoparticles described in the above technical solution in the preparation of tumor drugs.
[0020] The invention provides a method for preparing calcium peroxide nanoparticles wrapped in a metal polyphenol network, comprising the following steps: (1) mixing calcium peroxide nanoparticles, a drug and a first solvent, and then performing a chelating reaction to obtain drug-loaded calcium peroxide nanoparticles; (2) mixing a polymer solution and a polyphenol solution, and then performing a dehydration condensation reaction to obtain a polymer-modified polyphenol solution; (3) mixing the drug-loaded calcium peroxide nanoparticles obtained in step (1), a second solvent, the polymer-modified polyphenol solution obtained in step (2) and a metal salt solution, and then performing a coordination complexation reaction to obtain the calcium peroxide nanoparticles wrapped in a metal polyphenol network; steps (1) and (2) are not performed in any time sequence. The invention mixes calcium peroxide nanoparticles and drugs to obtain drug-loaded calcium peroxide nanoparticles, which are then mixed with a metal salt solution and a polymer-modified polyphenol solution for coordination and complexation reaction, and a metal polyphenol network is formed in situ on the surface of the drug-loaded calcium peroxide nanoparticles. The metal polyphenol-wrapped calcium peroxide nanoparticles protect the unstable calcium peroxide nanoparticles, thereby preventing the calcium peroxide nanoparticles from being exposed to hydrolysis prematurely before reaching the lesion site and the adverse reactions caused by the exposure. The metal ions released by the metal polyphenol-wrapped calcium peroxide nanoparticles catalyze hydrogen peroxide to generate hydroxyl radicals under acidic conditions, thereby killing tumor cells, thereby achieving chemodynamic therapy. , and metal ions can also consume glutathione, enhance the accumulation of reactive oxygen, and thus enhance the anti-tumor efficacy; when metal polyphenol-coated calcium peroxide nanoparticles are dispersed in an acidic environment, the metal polyphenol network layer will rapidly degrade, exposing the calcium peroxide nanoparticles and then explosively releasing a large amount of calcium ions and oxygen, which can more effectively activate calcium overload and alleviate the tumor hypoxic microenvironment; metal polyphenol network-coated drug-loaded calcium peroxide nanoparticles increase the effective accumulation of drugs at the tumor site by loading drugs, realize the combined treatment of chemodynamic therapy and chemotherapy, thereby activating anti-tumor immune response and improving anti-tumor effect. The results of the embodiment show that the metal polyphenol network-coated drug-loaded calcium peroxide nanoparticles prepared by the present invention have excellent anti-breast cancer effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The particle size of the CaO2 nanoparticles prepared in step (1) of Example 1 and the drug-loaded calcium peroxide nanoparticles prepared in Examples 1 to 6;
[0022] Figure 2 The encapsulation efficiency and drug loading of the drug-loaded calcium peroxide nanoparticles prepared in Examples 1 to 6;
[0023] Figure 3 The particle size of the CaO2 nanoparticles prepared in step (1) of Example 7, and the drug-loaded calcium peroxide nanoparticles prepared in Example 5 and Examples 7 to 11;
[0024] Figure 4 The encapsulation efficiency and drug loading of the drug-loaded calcium peroxide nanoparticles prepared in Examples 5 and 7 to 11;
[0025] Figure 5 is the particle size of the calcium peroxide nanoparticles encapsulated by the metal polyphenol network prepared in Examples 12 to 18;
[0026] Figure 6 It is a macroscopic picture of the calcium peroxide nanoparticle dispersion prepared in Example 12, the drug-loaded calcium peroxide nanoparticle dispersion prepared in Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticle dispersion prepared in Example 18, wherein from left to right are the calcium peroxide nanoparticle dispersion prepared in Example 12, the drug-loaded calcium peroxide nanoparticle dispersion prepared in Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticle dispersion prepared in Example 18;
[0027] Figure 7 The particle size diagram of the calcium peroxide nanoparticles prepared in step (1) of Example 12, the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18, wherein A is the calcium peroxide nanoparticles prepared in step (1) of Example 12, B is the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and C is the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18;
[0028] Figure 8 The average potential of the calcium peroxide nanoparticles prepared in step (1) of Example 12, the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18, wherein A is the calcium peroxide nanoparticles prepared in step (1) of Example 12, B is the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and C is the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18;
[0029] Fig. 9 is the particle size of CK@PTF nanoparticles prepared in Example 19;
[0030] Fig.10 is the particle size of CK@PTC nanoparticles prepared in Example 20;
[0031] Fig.11 The inhibition rate of kaempferol (KAE), calcium peroxide nanoparticles (CaO2) prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 on 4T1 cells at different administration concentrations;
[0032] Fig.12Effects of kaempferol (KAE) (4 μg / mL and 6 μg / mL) with (+) calcium chelator and without (-) calcium chelator, calcium peroxide nanoparticles (CaO2) prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 on the survival rate of 4T1 cells;
[0033] Fig.13 ROS content (20×) in 4T1 cells 12 h after administration of the blank control group, kaempferol (KAE), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18;
[0034] Fig.14 The curves of the changes in relative tumor volume of mice during treatment with the blank control group (Control), kaempferol (KAE), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18;
[0035] Fig.15 Pathological sections of mouse tumors after treatment with the blank control group (Control), kaempferol (KAE), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 (10×, 100 μm). DETAILED DESCRIPTION
[0036] The present invention provides a method for preparing metal polyphenol network-encapsulated calcium peroxide nanoparticles, comprising the following steps:
[0037] (1) mixing calcium peroxide nanoparticles, a drug, and a first solvent and performing a chelating reaction to obtain drug-loaded calcium peroxide nanoparticles;
[0038] (2) mixing the polymer solution and the polyphenol solution and performing a dehydration condensation reaction to obtain a polymer-modified polyphenol solution;
[0039] (3) mixing the drug-loaded calcium peroxide nanoparticles obtained in step (1) with a second solvent, the polymer-modified polyphenol solution obtained in step (2) and a metal salt solution, and performing a coordination complex reaction to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles;
[0040] There is no chronological order for steps (1) and (2).
[0041] Unless otherwise specified, the present invention has no particular limitation on the sources of the raw materials, and commercially available products known to those skilled in the art may be used.
[0042] The invention mixes calcium peroxide nanoparticles, drugs and a first solvent and then performs a chelating reaction to obtain drug-loaded calcium peroxide nanoparticles.
[0043] In the present invention, the particle size of the calcium peroxide nanoparticles is preferably 90 to 160 nm.
[0044] In the present invention, the method for preparing the calcium peroxide nanoparticles is preferably: mixing the calcium salt, the stabilizer, the third solvent, the alkaline solution and the hydrogen peroxide aqueous solution and then performing double decomposition reaction to obtain the calcium peroxide nanoparticles.
[0045] In the present invention, the calcium salt is preferably a soluble calcium salt, more preferably including one or more of calcium chloride, calcium hypochlorite, calcium chlorate, calcium perchlorate, calcium bicarbonate, calcium nitrate, calcium hydrogen phosphate, calcium sulfate, calcium hydrogen sulfate, calcium hydrogen sulfite, calcium oxalate, calcium permanganate, calcium iodide, calcium bromide, calcium gluconate and calcium lactate.
[0046] In the present invention, the stabilizer is preferably a high molecular polymer, more preferably hyaluronic acid or polyvinylpyrrolidone PVP, and further preferably polyvinylpyrrolidone PVP40. In the present invention, the stabilizer can coordinate with calcium ions to form a protective layer, thereby affecting the growth and aggregation of nanocrystals. With the help of the stabilizer, spherical aggregates with uniform size and polycrystalline structure can be obtained.
[0047] In the present invention, the mass ratio of the calcium salt to the stabilizer is preferably 1:(3-4), more preferably 1:3.5. The present invention limits the mass ratio of the calcium salt to the stabilizer to the above range, and can further obtain calcium peroxide nanoparticles of uniform size.
[0048] In the present invention, the third solvent is preferably an alcohol solution, more preferably anhydrous ethanol.
[0049] In the present invention, the mass ratio of the calcium salt to the volume ratio of the third solvent is preferably (6-7) mg:1 mL, more preferably (6.5-7) mg:1 mL. The present invention limits the mass ratio of the calcium salt to the volume ratio of the third solvent to the above range, which is more conducive to the dissolution of the calcium salt.
[0050] In the present invention, the concentration of the aqueous hydrogen peroxide solution is preferably 0.5 to 2 mol / L, more preferably 1 to 1.5 mol / L.
[0051] In the present invention, the ratio of the mass of the calcium salt to the amount of hydrogen peroxide in the aqueous hydrogen peroxide solution is preferably (0.1-1) g: 0.8 mmol, and more preferably (0.1-0.5) g: 0.8 mmol. The present invention limits the ratio of the mass of the calcium salt to the amount of hydrogen peroxide in the aqueous hydrogen peroxide solution to the above range, which is more conducive to the full reaction of the two to form calcium peroxide nanoparticles.
[0052] In the present invention, the alkaline solution preferably includes a weakly alkaline solution, and more preferably includes one or more of aqueous ammonia, aqueous sodium bicarbonate solution and aqueous sodium carbonate solution.
[0053] In the present invention, the mixture of the calcium salt, the stabilizer, the third solvent, the alkaline solution and the aqueous hydrogen peroxide solution is preferably: the calcium salt, the stabilizer and the third solvent are mixed to obtain a calcium salt solution, then the alkaline solution is added to obtain a reaction solution, and then the aqueous hydrogen peroxide solution is added. In the present invention, the pH value of the reaction solution is preferably 7 to 9, more preferably 8. The present invention has no special restrictions on the concentration and amount of the alkaline solution, and the pH value of the reaction solution is ensured to be within the above range.
[0054] In the present invention, the aqueous hydrogen peroxide solution is preferably added dropwise. The present invention has no particular limitation on the rate of the addition, and the rate of addition well known to those skilled in the art may be used. In the present invention, the addition can allow hydrogen peroxide to react more fully with the calcium salt to form calcium peroxide nanoparticles. In the present invention, the double decomposition reaction begins after the addition of the aqueous hydrogen peroxide solution begins.
[0055] In the present invention, the temperature of the double decomposition reaction is preferably 20 to 30°C; the time of the double decomposition reaction is preferably 0.01 to 48 hours, more preferably 5 to 36 hours. In the present invention, during the double decomposition reaction, the calcium salt and hydrogen peroxide react to form calcium peroxide nanoparticles. The present invention limits the temperature and time of the double decomposition reaction to the above range, so that the calcium salt and hydrogen peroxide can fully react.
[0056] After the double decomposition reaction is completed, the product of the double decomposition reaction is preferably centrifuged and washed in sequence to obtain calcium peroxide nanoparticles.
[0057] In the present invention, the centrifugal speed is preferably 10000-20000 rpm, more preferably 12000-18000 rpm; the centrifugal time is preferably 5-60 min, more preferably 10-40 min.
[0058] In the present invention, the solvent used in the washing is preferably anhydrous ethanol. The present invention has no special restrictions on the amount of the solvent used in the washing and the number of washing times, and the washing technical schemes well known to those skilled in the art can be used.
[0059] In the present invention, the drug preferably includes chemotherapeutic drugs, and more preferably includes one or more of kaempferol, gambogic acid, curcumin, elemene, celastrol, oridonin, brucea brucea oil, artemisinin, baicalin, ginsenoside, gallic acid, resveratrol, matrine, astragaloside, parifolin, icariin, notoginseng saponin, ligusticum chuanxiong, tanshinone, ursolic acid, cantharidin, ophiopogon saponin, platycodon saponin, apigenin, sinomenine, fisetin, fraxin, cinobuccalin, black rice anthocyanin, deguelin, andrographolide, quercetin, kochia saponin, osthole, paclitaxel, doxorubicin, camptothecin, fluorouracil, imatinib, cyclophosphamide, vincristine, mitoxantrone, bleomycin, nitrogen mustard hydrochloride, phenylalanine mustard, etoposide, vinorelbine, methotrexate and its derivatives.
[0060] In the present invention, the first solvent is preferably an alcohol solvent, more preferably anhydrous ethanol.
[0061] In the present invention, the mixing of the calcium peroxide nanoparticles, the drug and the first solvent is preferably: mixing the calcium peroxide nanoparticles with a portion of the first solvent to obtain a calcium peroxide nanoparticle dispersion; mixing the drug with the remaining first solvent to obtain a drug solution; and then mixing the calcium peroxide nanoparticle dispersion with the drug solution.
[0062] In the present invention, the concentration of the calcium peroxide nanoparticle dispersion is preferably 2 to 3 mg / mL, more preferably 2 to 2.5 mg / mL.
[0063] In the present invention, the concentration of the drug solution is preferably 300-800 μg / mL, more preferably 500-700 μg / mL, and further preferably 600 μg / mL. The present invention limits the concentration of the calcium peroxide nanoparticle dispersion and the drug solution to the above range, which can make the raw material dissolve or disperse more fully.
[0064] The present invention has no particular limitation on the amount of the first solvent, as long as the concentrations of the calcium peroxide nanoparticle dispersion and the drug solution are within the above range.
[0065] In the present invention, the volume ratio of the calcium peroxide nanoparticle dispersion and the drug solution is preferably (3-15): 1; the mass ratio of the calcium peroxide nanoparticles and the drug is preferably (2-60): 1, more preferably (5-50): 1. The present invention limits the volume ratio of the calcium peroxide nanoparticle dispersion and the drug solution, and the mass ratio of the calcium peroxide nanoparticles and the drug within the above ranges, which can increase the drug loading of the drug-loaded calcium peroxide nanoparticles and is more conducive to the treatment of tumors.
[0066] In the present invention, the temperature of the chelation reaction is preferably 4 to 40°C, more preferably 20 to 40°C; the time of the chelation reaction is preferably 1 to 48 hours, more preferably 12 to 48 hours, and further preferably 24 to 36 hours. In the present invention, during the chelation reaction, the drug is combined with calcium peroxide by chelation. The present invention limits the temperature and time of the chelation reaction within the above range, which can further increase the drug loading of the drug-loaded calcium peroxide nanoparticles.
[0067] After the chelation reaction is completed, the present invention preferably centrifuges and washes the product of the chelation reaction in sequence to obtain drug-loaded calcium peroxide nanoparticles.
[0068] In the present invention, the centrifugal speed is preferably 10000-20000 rpm, more preferably 12000-18000 rpm; the centrifugal time is preferably 5-60 min, more preferably 10-40 min.
[0069] In the present invention, the solvent used in the washing is preferably anhydrous ethanol. The present invention has no special restrictions on the amount of the solvent used in the washing and the number of washing times, and the washing technical schemes well known to those skilled in the art can be used.
[0070] The invention mixes a polymer solution with a polyphenol solution and then performs a dehydration condensation reaction to obtain a polymer-modified polyphenol solution.
[0071] In the present invention, the solvent in the polymer solution is preferably water, more preferably ultrapure water; the polymer in the polymer solution is preferably amino polyethylene glycol; the concentration of the polymer solution is preferably 8 to 12 mg / mL, more preferably 10 mg / mL. The present invention limits the concentration of the polymer solution to the above range so that it can be fully dissolved.
[0072] In the present invention, the solvent in the polyphenol solution is preferably a buffered salt solution, more preferably one of a phosphate buffer solution, a tris(hydroxymethyl)aminomethane buffer solution, a 3-morpholinepropanesulfonic acid buffer solution and a 4-hydroxyethylpiperazineethanesulfonic acid buffer solution. In the present invention, the pH value of the buffered salt solution is preferably 7 to 10, more preferably 8 to 9. The present invention uses a buffered salt solution as a solvent and limits its pH value to the above range, so that the system has a suitable pH value, which is more conducive to the reaction of the two.
[0073] In the present invention, the concentration of the polyphenol solution is preferably 2 to 3 mmol / L, more preferably 2 to 2.5 mmol / L. The present invention limits the concentration of the polyphenol solution to the above range to enable it to be fully dissolved.
[0074] In the present invention, the polyphenols in the polyphenol solution preferably include curcumin, quercetin, puerarin, catechin, proanthocyanidin, luteolin, hesperidin, naringenin, myricetin, rutin, erythrin, baicalin, ganetrin, taxol, syringaresin, apigenin, taxol, rambutanol, morin, tannin, hinoresin, rutin, paeonol, kaempferol, eriodictyol, brown algae polyphenols, polyflavanol polyphenols, One or more of phenol, mulberry glycoside, polydatin, podocarp glycoside, epidemethyltrachelogenin, resveratrol, pterostilbene, tannic acid, salvianolic acid, chlorogenic acid, gallic acid, caffeic acid, ellagic acid, digallic acid, propyl gallate, epigallocatechin gallate, galloylglucose, hydroxyhydroquinone, epicatechin gallate, catechin gallate, epigallocatechin gallate and their derivatives.
[0075] In the present invention, the mass ratio of the polymer in the polymer solution to the polyphenol in the polyphenol solution is preferably (1-3):1, more preferably (1.5-2):1. The present invention uses polymer to modify polyphenol to improve the dispersibility of the subsequently formed polyphenol network structure in water. The present invention limits the mass ratio of the polymer in the polymer solution to the polyphenol in the polyphenol solution within the above range, which is more conducive to the subsequent formation of the dispersibility of the metal polyphenol network structure in water and further improves its tumor treatment effect.
[0076] In the present invention, the temperature of the dehydration condensation reaction is preferably 4 to 40°C, more preferably 10 to 40°C, and further preferably 20 to 40°C; the time of the dehydration condensation reaction is preferably 1 to 48 hours, more preferably 1 to 36 hours, and further preferably 1 to 12 hours. The present invention limits the temperature and time of the dehydration condensation reaction to the above ranges, so that the polyphenol and the polymer can react fully.
[0077] After obtaining drug-loaded calcium peroxide nanoparticles and polymer-modified polyphenol solution, the present invention mixes the drug-loaded calcium peroxide nanoparticles with a second solvent, the polymer-modified polyphenol solution and a metal salt solution, and then performs a coordination complex reaction to obtain metal polyphenol network-wrapped calcium peroxide nanoparticles.
[0078] In the present invention, the second solvent is preferably an alcohol solvent, more preferably anhydrous ethanol.
[0079] In the present invention, the mass ratio of the drug-loaded calcium peroxide nanoparticles to the volume ratio of the second solvent is preferably (1-2) mg:1 mL, more preferably (1.5-2) mg:1 mL. The present invention limits the mass ratio of the drug-loaded calcium peroxide nanoparticles to the volume ratio of the second solvent to the above range, so that they can be fully dispersed.
[0080] In the present invention, the solvent in the metal salt solution is preferably a buffered salt solution, more preferably one of a phosphate buffer solution, a tris(hydroxymethyl)aminomethane buffer solution, a 3-morpholinepropanesulfonic acid buffer solution and a 4-hydroxyethylpiperazineethanesulfonic acid buffer solution. In the present invention, the pH value of the buffered salt solution is preferably 7 to 10, more preferably 8 to 9. The present invention uses a buffered salt solution as a solvent and limits its pH value to the above range, so that the system has a suitable pH value, which is more conducive to the coordination complex reaction.
[0081] In the present invention, the metal in the metal salt solution preferably includes one or more of Ag, Au, Al, Ba, Bi, Ca, Cd, Ce, Co, Cr, Cu, Eu, Fe, Fe, Gd, Mg, Mn, Mn, Mo, Ni, Pt, W, V, Zn and Zr. The present invention has no particular limitation on the type of the metal salt, and metal salts well known to those skilled in the art can be used.
[0082] In the present invention, the concentration of the metal salt solution is preferably 2 to 3 mmol / L, more preferably 2 to 2.5 mmol / L.
[0083] In the present invention, the molar ratio of the polyphenols in the polyphenol solution to the metal ions in the metal salt solution is preferably (0.5-10): 1, and more preferably (2-8): 1. The present invention limits the molar ratio of the polyphenols in the polyphenol solution to the metal ions in the metal salt solution within the above range, so that the metal ions and the polyphenols can fully undergo coordination and complexation reaction to form a network structure to encapsulate the drug-loaded calcium peroxide nanoparticles, further improving the tumor treatment effect thereof.
[0084] In the present invention, the molar ratio of calcium peroxide in the drug-loaded calcium peroxide nanoparticles to metal ions in the metal salt solution is preferably (20-50): 1, and more preferably (25-40): 1. The present invention limits the molar ratio of calcium peroxide in the drug-loaded calcium peroxide nanoparticles to metal ions in the metal salt solution within the above range, so that the formed metal polyphenol network structure can more fully wrap the drug-loaded calcium peroxide nanoparticles, further improving its tumor treatment effect.
[0085] In the present invention, the volume ratio of the polymer-modified polyphenol solution to the metal salt solution is preferably 1:(0.8-1.2), more preferably 1:1.
[0086] In the present invention, the mixing of the drug-loaded calcium peroxide nanoparticles and the second solvent, the polymer-modified polyphenol solution and the metal salt solution is preferably: mixing the drug-loaded calcium peroxide nanoparticles and the second solvent to obtain a drug-loaded calcium peroxide nanoparticle dispersion, then adding the metal salt solution, and then adding the polymer-modified polyphenol solution.
[0087] In the present invention, the metal salt solution is preferably added slowly. The present invention has no particular limitation on the rate of slow addition, and it only needs to be relatively slow.
[0088] In the present invention, the polymer-modified polyphenol solution is preferably added dropwise. The present invention has no particular limitation on the rate of the dropping, and the dropping technique known to those skilled in the art can be used.
[0089] In the present invention, the temperature of the coordination complex reaction is preferably 4 to 40°C, more preferably 10 to 40°C, and further preferably 20 to 40°C; the time of the coordination complex reaction is preferably 1 to 48h, more preferably 12 to 48h, and more preferably 24 to 36h. In the present invention, during the coordination complex reaction, the metal ions in the metal salt react with the polyphenols to form a network structure to encapsulate the drug-loaded calcium peroxide nanoparticles. The present invention limits the temperature and time of the coordination complex reaction within the above range, so that the metal ions and the polyphenols can fully react to encapsulate the drug-loaded calcium peroxide nanoparticles, further improving its tumor treatment effect.
[0090] After the coordination and complexing reaction is completed, the product of the coordination and complexing reaction is preferably centrifuged, washed and redispersed in sequence.
[0091] In the present invention, the centrifugal speed is preferably 5000-20000 rpm, more preferably 10000-15000 rpm; the centrifugal time is preferably 5-60 min, more preferably 10-40 min.
[0092] In the present invention, the solvent used in the washing is preferably ethanol. The present invention has no special restrictions on the amount of the solvent used in the washing and the number of washing times, and the washing technical schemes well known to those skilled in the art can be used.
[0093] In the present invention, the solvent for redispersion is preferably ultrapure water.
[0094] The metal polyphenol-coated calcium peroxide nanoparticles of the present invention play a protective role on unstable calcium peroxide nanoparticles; the released metal ions catalyze hydrogen peroxide to generate hydroxyl radicals under acidic conditions, thereby killing tumor cells and realizing chemodynamic therapy, and can also consume glutathione, enhance the accumulation of active oxygen, and thereby enhance the anti-tumor efficacy; when dispersed in an acidic environment, the metal polyphenol network layer will be rapidly degraded, exposing the calcium peroxide nanoparticles and then explosively releasing a large amount of calcium ions and oxygen, which can more effectively activate calcium overload and alleviate the hypoxic microenvironment of the tumor; by loading drugs, the effective accumulation of drugs at the tumor site is improved, and the combined treatment of chemodynamic therapy and chemotherapy is realized, thereby activating the anti-tumor immune response and improving the anti-tumor effect.
[0095] The present invention provides metal polyphenol network-wrapped calcium peroxide nanoparticles prepared by the preparation method described in the above technical scheme, comprising drug-loaded calcium peroxide nanoparticles and metal polyphenol networks wrapped on the surfaces of the drug-loaded calcium peroxide nanoparticles.
[0096] The metal polyphenol network-wrapped calcium peroxide nanoparticles prepared by the present invention have better tumor treatment effect.
[0097] The present invention also provides the use of the metal polyphenol network-encapsulated calcium peroxide nanoparticles described in the above technical solution in the preparation of tumor drugs.
[0098] The present invention has no special limitation on the technical scheme of using the metal polyphenol network-encapsulated calcium peroxide nanoparticles in preparing tumor drugs, and the technical scheme of using the metal polyphenol network-encapsulated calcium peroxide nanoparticles in preparing tumor drugs well known to those skilled in the art can be used.
[0099] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0100] Example 1
[0101] (1) 0.4 g of calcium chloride and 1.4 g of polyvinylpyrrolidone PVP40 were dissolved in 60 mL of anhydrous ethanol (the mass ratio of calcium chloride to the volume ratio of anhydrous ethanol was 6.7 mg: 1 mL), and then 4 mL of 0.8 mol / L ammonia water was added at 25 ° C with stirring until the pH value of the solution was 8, and then 0.8 mL of 1 mol / L hydrogen peroxide aqueous solution was added dropwise (the mass ratio of calcium chloride to polyvinylpyrrolidone PVP40 was 1:3.5, and the mass ratio of calcium chloride to the amount of hydrogen peroxide in the hydrogen peroxide aqueous solution was 0.4 g: 0.8 mmol). After the addition was completed, the mixture was stirred for 2 min. After the reaction was completed, the mixture was centrifuged at a speed of 15000 rpm for 20 min, and calcium peroxide nanoparticles were collected and washed with ethanol for 5 times to obtain calcium peroxide nanoparticles, which were recorded as CaO2 nanoparticles;
[0102] (2) The calcium peroxide nanoparticles obtained in step (1) were mixed with 15 mL of anhydrous ethanol to obtain a calcium peroxide nanoparticle dispersion with a concentration of 2.14 mg / mL; kaempferol KAE was mixed with anhydrous ethanol to obtain a kaempferol solution with a concentration of 600 μg / mL; the calcium peroxide nanoparticle dispersion and the kaempferol solution were mixed in a volume ratio of 15:1 (the mass ratio of calcium peroxide nanoparticles to kaempferol was 53.5:1), and a chelating reaction was carried out at 25° C. for 24 h, and the mixture was centrifuged at 15,000 rpm for 20 min to collect the calcium peroxide nanoparticles loaded with kaempferol, which were recorded as CK nanoparticles.
[0103] Example 2
[0104] The volume ratio of the calcium peroxide nanoparticle dispersion and the kaempferol solution in step (2) of Example 1 was replaced with 12:1. At this time, the mass ratio of the calcium peroxide nanoparticles and kaempferol was 42.8:1. The other parameters were the same as those in Example 1.
[0105] Example 3
[0106] The volume ratio of the calcium peroxide nanoparticle dispersion and the kaempferol solution in step (2) of Example 1 was replaced with 10:1. At this time, the mass ratio of the calcium peroxide nanoparticles and kaempferol was 35.7:1. The other parameters were the same as those in Example 1.
[0107] Example 4
[0108] The volume ratio of the calcium peroxide nanoparticle dispersion and the kaempferol solution in step (2) of Example 1 was replaced with 7:1. At this time, the mass ratio of the calcium peroxide nanoparticles and kaempferol was 25:1. The other parameters were the same as those in Example 1.
[0109] Example 5
[0110] The volume ratio of the calcium peroxide nanoparticle dispersion and the kaempferol solution in step (2) of Example 1 was replaced with 5:1. At this time, the mass ratio of the calcium peroxide nanoparticles and kaempferol was 17.8:1. The other parameters were the same as those in Example 1.
[0111] Example 6
[0112] The volume ratio of the calcium peroxide nanoparticle dispersion and the kaempferol solution in step (2) of Example 1 was replaced with 3:1. At this time, the mass ratio of the calcium peroxide nanoparticles and kaempferol was 10.7:1. The other parameters were the same as those in Example 1.
[0113] The particle sizes of the CaO2 nanoparticles prepared in step (1) of Example 1 and the drug-loaded calcium peroxide nanoparticles prepared in Examples 1 to 6 were measured. Figure 1 The encapsulation efficiency and drug loading of the drug-loaded calcium peroxide nanoparticles prepared in Examples 1 to 6 were measured, and the results were as follows: Figure 2As shown, the specific test steps for encapsulation efficiency and drug loading are as follows: the system after the chelation reaction of Examples 1 to 6 is centrifuged at 14000 rpm and 4°C for 20 min, the supernatant is taken, and the nanoparticles after centrifugation are washed twice with ethanol, centrifuged at 14000 rpm and 4°C for 20 min, the supernatant is collected, the three supernatants are combined, the absorbance is measured at the maximum absorption wavelength, and the free content is calculated according to the linear curve, which is recorded as W 游 The content of kaempferol initially added is recorded as W 总 The total amount of CK nanoparticles is recorded as W, and the encapsulation efficiency is calculated according to the formula: Encapsulation efficiency (%) = [(W 总- W 游 ) / W 总 ]×100%, and calculate the drug loading according to the formula: drug loading (%) = [(W 总- W 游 ) / W]×100%, each example was measured 3 times and the average value was taken. Figure 1 and Figure 2 It can be seen that with the decrease of the volume ratio of calcium peroxide nanoparticles dispersion and kaempferol solution, that is, the decrease of the mass ratio of calcium peroxide nanoparticles and kaempferol, the particle size of CK nanoparticles did not change significantly, the encapsulation efficiency gradually decreased, and the drug loading amount gradually increased.
[0114] Example 7
[0115] (1) 0.4 g of calcium chloride and 1.4 g of polyvinylpyrrolidone PVP40 were dissolved in 60 mL of anhydrous ethanol (the mass ratio of calcium chloride to the volume ratio of anhydrous ethanol was 6.7 mg: 1 mL), and then 4 mL of 0.8 mol / L ammonia water was added at 25 ° C with stirring until the pH value of the solution was 8, and then 0.8 mL of 1 mol / L hydrogen peroxide aqueous solution was added dropwise (the mass ratio of calcium chloride to polyvinylpyrrolidone PVP40 was 1:3.5, and the mass ratio of calcium chloride to the amount of hydrogen peroxide in the hydrogen peroxide aqueous solution was 0.4 g: 0.8 mmol). After the addition was completed, the mixture was stirred for 2 min. After the reaction was completed, the mixture was centrifuged at a speed of 15000 rpm for 20 min, and calcium peroxide nanoparticles were collected and washed with ethanol for 5 times to obtain calcium peroxide nanoparticles, which were recorded as CaO2 nanoparticles;
[0116] (2) The calcium peroxide nanoparticles obtained in step (1) were mixed with 1.5 mL of anhydrous ethanol to obtain a calcium peroxide nanoparticle dispersion with a concentration of 2.14 mg / mL; kaempferol KAE was mixed with anhydrous ethanol to obtain a kaempferol solution with a concentration of 300 μg / mL; 1.5 mL of the calcium peroxide nanoparticle dispersion and 300 μL of the kaempferol solution were mixed (the mass ratio of the calcium peroxide nanoparticles to the kaempferol was 35.7:1), and a chelating reaction was carried out at 25° C. for 24 h, and the mixture was centrifuged at 15,000 rpm for 20 min, and the calcium peroxide nanoparticles loaded with kaempferol were collected and recorded as CK nanoparticles.
[0117] Example 8
[0118] The concentration of the kaempferol solution in step (2) of Example 7 was replaced with 400 μg / mL. At this time, the mass ratio of calcium peroxide nanoparticles to kaempferol was 26.75:1. Other parameters were the same as those in Example 7.
[0119] Example 9
[0120] The concentration of the kaempferol solution in step (2) of Example 7 was replaced with 500 μg / mL. At this time, the mass ratio of calcium peroxide nanoparticles to kaempferol was 21.4:1. Other parameters were the same as those in Example 7.
[0121] Example 10
[0122] The concentration of the kaempferol solution in step (2) of Example 7 was replaced with 700 μg / mL. At this time, the mass ratio of calcium peroxide nanoparticles to kaempferol was 15.29:1. Other parameters were the same as those in Example 7.
[0123] Embodiment 11
[0124] The concentration of the kaempferol solution in step (2) of Example 7 was replaced with 800 μg / mL. At this time, the mass ratio of calcium peroxide nanoparticles to kaempferol was 13.375:1. Other parameters were the same as those in Example 7.
[0125] The same test method was used to measure the particle sizes of the CaO2 nanoparticles prepared in step (1) of Example 7, the drug-loaded calcium peroxide nanoparticles prepared in Example 5, and the drug-loaded calcium peroxide nanoparticles prepared in Examples 7 to 11. The results are as follows: Figure 3 The encapsulation efficiency and drug loading of the drug-loaded calcium peroxide nanoparticles prepared in Example 5 and the drug-loaded calcium peroxide nanoparticles prepared in Examples 7 to 11 were measured. The results are shown in Figure 4 As shown. Figure 3 and Figure 4 It can be seen that with the increase of KAE concentration, the particle size of CK nanoparticles did not change significantly, the encapsulation efficiency gradually decreased, and the drug loading amount gradually increased.
[0126] Example 12
[0127] (1) 0.4 g of calcium chloride and 1.4 g of polyvinylpyrrolidone PVP40 were dissolved in 60 mL of anhydrous ethanol (the mass ratio of calcium chloride to the volume ratio of anhydrous ethanol was 6.7 mg: 1 mL), and then 4 mL of 0.8 mol / L ammonia water was added at 25 ° C with stirring until the pH value of the solution was 8, and then 0.8 mL of 1 mol / L hydrogen peroxide aqueous solution was added dropwise (the mass ratio of calcium chloride to polyvinylpyrrolidone PVP40 was 1:3.5, and the mass ratio of calcium chloride to the amount of hydrogen peroxide in the hydrogen peroxide aqueous solution was 0.4 g: 0.8 mmol). After the addition was completed, the mixture was stirred for 2 min. After the reaction was completed, the mixture was centrifuged at a speed of 15000 rpm for 20 min, and calcium peroxide nanoparticles were collected and washed with ethanol for 5 times to obtain calcium peroxide nanoparticles, which were recorded as CaO2 nanoparticles;
[0128] (2) mixing the calcium peroxide nanoparticles obtained in step (1) with 15 mL of anhydrous ethanol to obtain a calcium peroxide nanoparticle dispersion with a concentration of 2.14 mg / mL; mixing kaempferol KAE with anhydrous ethanol to obtain a kaempferol solution with a concentration of 600 μg / mL; mixing the calcium peroxide nanoparticle dispersion with the kaempferol solution in a volume ratio of 5:1 (the mass ratio of calcium peroxide nanoparticles to kaempferol is 17.8:1), performing a chelating reaction at 25° C. for 24 h, centrifuging at 15000 rpm for 20 min, and collecting the calcium peroxide nanoparticles loaded with kaempferol, which are recorded as CK nanoparticles;
[0129] (3) Add 2 mL of 10 mg / mL aqueous solution of amino-modified polyethylene glycol to 3 mL of 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L tannic acid (relative molecular weight 1701.2, MacLean CAS No.: 1401-55-4, catalog number: T818845) (the pH value of the buffer solution is 8, and the mass ratio of amino-modified polyethylene glycol to tannic acid is 5:3), and react at 25°C for 1 h to obtain a polyethylene glycol-modified tannic acid solution, which is recorded as PEG-TA solution;
[0130] (4) The calcium peroxide nanoparticles loaded with kaempferol prepared in step (2) were mixed with 18 mL of anhydrous ethanol (the mass ratio of the calcium peroxide nanoparticles loaded with kaempferol to the volume ratio of anhydrous ethanol was 1.68 mg:1 mL) to obtain a dispersion of drug-loaded calcium peroxide nanoparticles with a concentration of 1.68 mg / mL, 0.4 mL of 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride (the pH value of the buffer solution was 8) was slowly added, and then an equal volume (0.4 mL) of PEG-T prepared in step (3) was dropwise added. A solution (the volume ratio of PEG-TA solution to the volume of 3-morpholinepropanesulfonic acid buffer solution containing manganese chloride is 1:1, the molar ratio of tannic acid to manganese ions is 5:8, and the molar ratio of calcium peroxide to manganese ions in calcium peroxide nanoparticles loaded with kaempferol is 46:1), stirred at 25°C for 24h, centrifuged at 10000rpm for 10min, washed twice with ethanol, and then dispersed in 1.5mL ultrapure water to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles, recorded as CK@PTM nanoparticles.
[0131] Embodiment 13
[0132] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced by 0.45 mL, and the volume of the PEG-TA solution was replaced by 0.45 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 41:1. Other parameters were the same as in Example 12.
[0133] Embodiment 14
[0134] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced by 0.5 mL, and the volume of the PEG-TA solution was replaced by 0.5 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 37:1. Other parameters were the same as in Example 12.
[0135] Embodiment 15
[0136] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced by 0.55 mL, and the volume of the PEG-TA solution was replaced by 0.55 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 34:1. Other parameters were the same as in Example 12.
[0137] Example 16
[0138] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced with 0.6 mL, and the volume of the PEG-TA solution was replaced with 0.6 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 31:1. Other parameters were the same as in Example 12.
[0139] Embodiment 17
[0140] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced by 0.65 mL, and the volume of the PEG-TA solution was replaced by 0.65 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 29:1. Other parameters were the same as in Example 12.
[0141] Embodiment 18
[0142] The volume of the 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L manganese chloride in step (4) of Example 12 was replaced by 0.7 mL, and the volume of the PEG-TA solution was replaced by 0.7 mL. At this time, the molar ratio of tannic acid to manganese ions was 5:8, and the molar ratio of calcium peroxide to manganese ions in the calcium peroxide nanoparticles loaded with kaempferol was 26:1. Other parameters were the same as in Example 12.
[0143] The same test method was used to test the particle size of the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Examples 12 to 18. The results are as follows: Figure 5 As shown. Figure 5 It can be seen that with the gradual increase in the volume of manganese chloride and tannic acid added, the particle size of CK@PTM nanoparticles also gradually increases.
[0144] The macroscopic images of the calcium peroxide nanoparticle dispersion prepared in Example 12, the drug-loaded calcium peroxide nanoparticle dispersion prepared in Example 13, and the metal polyphenol network-encapsulated calcium peroxide nanoparticle dispersion prepared in Example 18 are as follows: Figure 6 As shown, from left to right are calcium peroxide nanoparticle dispersion, drug-loaded calcium peroxide nanoparticle dispersion, and metal polyphenol network-encapsulated calcium peroxide nanoparticle dispersion. Figure 6 It can be seen that the appearance colors of the calcium peroxide nanoparticle dispersion, drug-loaded calcium peroxide nanoparticle dispersion and metal polyphenol network-encapsulated calcium peroxide nanoparticle dispersion are light blue, yellow and brown, respectively. The changes in their appearance colors indirectly verify the successful synthesis of CK@PTM nanoparticles.
[0145] The particle sizes of the calcium peroxide nanoparticles prepared in step (1) of Example 12, the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18 were measured. The results are as follows: Figure 7 As shown, A is the calcium peroxide nanoparticles prepared in step (1) of Example 12, B is the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and C is the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18. Figure 7 It can be seen that the average particle sizes of CaO2, CK and CK@PTM nanoparticles are 114.9±2.62nm, 101.3±0.74nm and 138.0±1.07nm, respectively.
[0146] The average potential of the calcium peroxide nanoparticles prepared in step (1) of Example 12, the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18 were tested. The results are as follows: Figure 8 As shown, A is the calcium peroxide nanoparticles prepared in step (1) of Example 12, B is the drug-loaded calcium peroxide nanoparticles prepared in step (2) of Example 12, and C is the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared in Example 18. Figure 8 It can be seen that the average potentials of CaO2, CK and CK@PTM nanoparticles are 1.63±0.19mV, -31.6±0.19mV and -11.5±2.83mV, respectively.
[0147] Embodiment 19
[0148] (1) 0.4 g of calcium chloride and 1.4 g of polyvinylpyrrolidone PVP40 were dissolved in 60 mL of anhydrous ethanol (the mass ratio of calcium chloride to the volume ratio of anhydrous ethanol was 6.7 mg: 1 mL), and then 4 mL of 0.8 mol / L ammonia water was added at 25 ° C with stirring until the pH value of the solution was 8, and then 0.8 mL of 1 mol / L hydrogen peroxide aqueous solution was added dropwise (the mass ratio of calcium chloride to polyvinylpyrrolidone PVP40 was 1:3.5, and the mass ratio of calcium chloride to the amount of hydrogen peroxide in the hydrogen peroxide aqueous solution was 0.4 g: 0.8 mmol). After the addition was completed, the mixture was stirred for 2 min. After the reaction was completed, the mixture was centrifuged at a speed of 15000 rpm for 20 min, and calcium peroxide nanoparticles were collected and washed with ethanol for 5 times to obtain calcium peroxide nanoparticles, which were recorded as CaO2 nanoparticles;
[0149] (2) mixing the calcium peroxide nanoparticles obtained in step (1) with 15 mL of anhydrous ethanol to obtain a calcium peroxide nanoparticle dispersion with a concentration of 2.14 mg / mL; mixing kaempferol KAE with anhydrous ethanol to obtain a kaempferol solution with a concentration of 600 μg / mL; mixing the calcium peroxide nanoparticle dispersion with the kaempferol solution in a volume ratio of 5:1 (the mass ratio of calcium peroxide nanoparticles to kaempferol is 17.8:1), performing a chelating reaction at 25° C. for 24 h, centrifuging at 15000 rpm for 20 min, and collecting the calcium peroxide nanoparticles loaded with kaempferol, which are recorded as CK nanoparticles;
[0150] (3) Add 2 mL of 10 mg / mL aqueous solution of amino-modified polyethylene glycol to 3 mL of 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L tannic acid (the pH value of the buffer solution is 8, and the mass ratio of amino-modified polyethylene glycol to tannic acid is 5:3), and react at 25°C for 1 h to obtain a polyethylene glycol-modified tannic acid solution, which is recorded as PEG-TA solution;
[0151] (4) The calcium peroxide nanoparticles loaded with kaempferol prepared in step (2) were mixed with 18 mL of anhydrous ethanol (the mass ratio of the calcium peroxide nanoparticles loaded with kaempferol to the volume ratio of anhydrous ethanol was 1.68 mg:1 mL) to obtain a dispersion of drug-loaded calcium peroxide nanoparticles with a concentration of 1.68 mg / mL, 0.7 mL of 3-morpholinepropanesulfonic acid buffer solution containing 2.4 mmol / L ferric chloride (the pH value of the buffer solution was 8) was slowly added, and then an equal volume of the PEG-TA solution obtained in step (3) was dropwise added ( The ratio of the volume of PEG-TA solution to the total volume of 3-morpholinepropanesulfonic acid buffer solution containing ferric chloride is 1:1, the molar ratio of tannic acid to iron ions is 5:8, and the molar ratio of calcium peroxide to iron ions in calcium peroxide nanoparticles loaded with kaempferol is 26:1), the reaction is stirred at 25°C for 24 hours, centrifuged at 10000 rpm for 10 minutes, washed twice with ethanol, and then dispersed in 1.5 mL of ultrapure water to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles, recorded as CK@PTF nanoparticles.
[0152] The particle size of the CK@PTF nanoparticles obtained in Example 19 was measured three times. The results are as follows: Fig. 9 As shown. Fig. 9 It can be seen that the particle size and PDI of CK@PTF nanoparticles are 156.5 nm and 0.135, respectively.
[0153] Embodiment 20
[0154] The 3-morpholinepropanesulfonic acid buffer solution containing ferric chloride in step (4) of Example 19 was replaced with a 3-morpholinepropanesulfonic acid buffer solution containing cupric chloride, and other parameters were the same as in Example 19 to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles, which were recorded as CK@PTC nanoparticles.
[0155] The particle size of the CK@PTC nanoparticles obtained in Example 20 was measured three times. The results are as follows: Fig.10 As shown. Fig.10 It can be seen that the particle size and PDI of CK@PTC nanoparticles are 199.8 nm and 0.207, respectively.
[0156] Application Example 1
[0157] The in vitro antitumor effects of kaempferol, calcium peroxide nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 were tested respectively: breast cancer 4T1 cells in the logarithmic growth phase were taken and cultured at 2.5×10 4 The cells were inoculated at a density of cells / mL in a 96-well cell culture plate and cultured in a cell culture incubator at 37°C and 5% CO2. When the cell density reached 75%, the old culture medium was discarded, and fresh culture medium containing kaempferol (KAE) at different concentrations (2, 4, 6, 8, 10 μg / mL), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 were added to the experimental groups, respectively. Three replicate wells were set up for each group. The 96-well cell culture plate was then cultured for a further 24 hours. The old culture medium was discarded, and 100 μL of culture medium containing 10% CCK-8 was added to each well. The plates were placed in an incubator for incubation for 2 hours, then taken out and the absorbance of each well at a wavelength of 450 nm was measured using a full-wavelength microplate reader to calculate the cell inhibition rate. The results are shown in the figure. Fig.11 As shown. Fig.11 It can be seen that all experimental groups showed obvious concentration dependence in their cytotoxicity to 4T1 cells. When the administration concentration was 10 μg / mL, the inhibition rates of kaempferol (KAE), CaO2 nanoparticles, CK nanoparticles and CK@PTM nanoparticles on 4T1 cells were 15.46±3.91%, 64.89±4.00%, 83.01±1.55% and 90.61±0.94%, respectively, indicating that CK@PTM nanoparticles have good anti-tumor effects in vitro.
[0158] Breast cancer 4T1 cells in the logarithmic growth phase were collected and plated at 2.5×10 4The cells were inoculated at a density of 100 μg / mL in a 96-well cell culture plate and cultured in a cell culture incubator at 37°C and 5% CO2. When the cell density reached 75%, the old culture medium was discarded, and fresh culture medium containing kaempferol (KAE) without calcium chelator and 4 μg / mL calcium chelator (the concentrations of kaempferol were 4 μg / mL and 6 μg / mL, respectively), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 were added to the experimental groups, and 3 replicate wells were set up for each group. The 96-well cell culture plate was then cultured for a further 24 hours. The old culture medium was discarded, and 100 μL of culture medium containing 10% CCK-8 was added to each well. The plates were placed in an incubator for incubation for 2 hours, then taken out, and the absorbance of each well at a wavelength of 450 nm was measured using a full-wavelength microplate reader to calculate the cell inhibition rate. The results are shown in the table below. Fig.12 As shown. Fig.12 It can be seen that after the addition of calcium chelators, the cell survival rates of the remaining groups were improved except for the blank control group and the kaempferol group, indicating that calcium overload is one of the reasons why CaO2 nanoparticles, CK nanoparticles and CK@PTM nanoparticles induce 4T1 cell death.
[0159] 4T1 cells in the logarithmic growth phase were taken and 3×10 4 The cells were seeded at a density of 100 μg / mL in a 48-well plate and placed in an incubator for further culture. When the cells were fused to 75%, the old culture medium was removed, and fresh culture medium containing kaempferol (KAE) at different concentrations (4 μg / mL, 6 μg / mL), CaO2 nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 were added respectively, with 3 replicate wells set up for each group. After incubation in the incubator for 12 hours, the culture medium was removed, DCFH-DA (10 μM) dye solution was added to each well, and the plates were incubated at 37°C for 20 minutes. The fluorescence signals were observed under a fluorescence microscope, and images were collected and analyzed. The results are shown as follows. Fig.13 As shown. Fig.13 It can be seen that there is almost no green fluorescence in the cell blank control group (Control), and a weaker green fluorescence signal is shown in the kaempferol group, indicating that kaempferol can promote the production of ROS in 4T1 cells. Due to the dual effects of CaO2 nanoparticles and kaempferol, the fluorescence signal of the CK nanoparticle group is slightly larger than that of the CaO2 nanoparticle group, and the CK@PTM nanoparticle group shows the strongest fluorescence signal, which can be attributed to the triple effects of CaO2, kaempferol and metal polyphenol network.
[0160] Application Example 2
[0161] The in vivo antitumor effects of kaempferol, calcium peroxide nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 were tested respectively: 4T1 cells in the logarithmic growth phase were taken, and 0.1 mL of the cells were diluted with 1.5×10 7 The cell suspension of 100 cells / mL was inoculated into the fat pad of the fourth nipple on the right side of the mouse. After the inoculation, the growth of the tumor was observed daily, and the long diameter (a, in mm) and short diameter (b, in mm) of the mouse tumor were measured and recorded using a vernier caliper. The tumor volume formula V = a × b 2 / 2, calculate the tumor volume of the mouse, and wait until the tumor volume reaches 100mm 3 The model was successfully established when . The tumor-bearing mice were randomly divided into 5 groups and injected with physiological saline, kaempferol (KAE), calcium peroxide nanoparticles prepared in step (1) of Example 12, CK nanoparticles prepared in step (2) of Example 12, and CK@PTM nanoparticles prepared in Example 18 through tail vein injection. The drugs were administered once every 2 days at a dose of 2 mg / kg, and a total of 7 doses were administered. Before each administration, a vernier caliper was used to measure and calculate the tumor volume of each group of mice, and a curve of the change in tumor volume during the treatment was drawn. After the treatment, the mice were killed, the tumor tissues were taken, photographed and weighed, the tumor size and body weight of different groups were compared, and the tumor inhibition rate was calculated. Subsequently, the tumor tissues were embedded in paraffin, and the apoptosis of tumor cells was detected by HE staining, TUNEL staining test and Ki67 staining, and the in vivo anti-tumor effect of CK@PTM nanoparticles was investigated. The results are shown in Figure 2. Fig.14 and Fig.15 As shown. Fig.14 It can be seen that the relative tumor volume of each group of mice showed an upward trend, but the growth rate was different. The normal saline (Control) group grew the fastest, followed by the kaempferol (KAE) group. There was no significant difference in the growth rate between the CaO2 nanoparticle group and the CK nanoparticle group. The CK@PTM group grew the slowest, indicating that CK@PTM nanoparticles have a good inhibitory effect on tumor growth. Fig.15It can be seen from the results of HE staining that the tumor cells in the saline (Control) group had a large density, complete cell morphology, and good growth status. The kaempferol (KAE) group showed a certain degree of nuclear shrinkage and nuclear dissolution. The CaO2 nanoparticle group, CK nanoparticle group, and CK@PTM nanoparticle group all showed large-area nuclear dissolution and atrophy and deformation. Among them, the tumor tissue in the CK@PTM nanoparticle group was the most severely damaged. The results of Ki67 staining showed that there were a large number of tumor cells in the normal saline (Control) group that were in the process of proliferation, accounting for 63.30±4.30%. The proportion of brown in the kaempferol (KAE) group was significantly reduced, and there were a small number of tumor cells in the process of proliferation. In the proliferating tumor cells (36.63±2.07%), there were almost no proliferating cells in the CaO2 nanoparticle group, CK nanoparticle group and CK@PTM nanoparticle group, indicating that CK@PTM nanoparticles can significantly inhibit the proliferation of tumor cells; TUNEL staining results showed that there were only a small number of apoptotic tumor cells in the saline (Control) group. Compared with the control group, the apoptotic tumor cells in the kaempferol (KAE) group increased significantly. There were a large number of apoptotic tumor cells in the CaO2 nanoparticle group, CK nanoparticle group and CK@PTM nanoparticle group, accounting for 81.77±3.82%, which was consistent with the results of HE staining and TUNEL staining. The above results show that CK@PTM nanoparticles can significantly inhibit the proliferation of tumor cells and have a strong tumor killing effect.
[0162] In summary, the metal polyphenol network-encapsulated calcium peroxide nanoparticles prepared by the present invention realizes the combined treatment of chemodynamic therapy and chemotherapy and has a better anti-tumor effect.
[0163] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing metal polyphenol network-encapsulated calcium peroxide nanoparticles, comprising the following steps: (1) mixing calcium peroxide nanoparticles, a drug, and a first solvent and performing a chelating reaction to obtain drug-loaded calcium peroxide nanoparticles; (2) mixing the polymer solution and the polyphenol solution and performing a dehydration condensation reaction to obtain a polymer-modified polyphenol solution; (3) mixing the drug-loaded calcium peroxide nanoparticles obtained in step (1) with a second solvent, the polymer-modified polyphenol solution obtained in step (2) and a metal salt solution, and performing a coordination complex reaction to obtain metal polyphenol network-encapsulated calcium peroxide nanoparticles; There is no chronological order for steps (1) and (2).
2. The preparation method according to claim 1, characterized in that: In the step (1), the mass ratio of calcium peroxide nanoparticles to the drug is (10-55):
1.
3. The preparation method according to claim 1, characterized in that: The temperature of the chelating reaction in step (1) is 4 to 40° C., and the time of the chelating reaction is 1 to 48 hours.
4. The preparation method according to claim 1, characterized in that: The mass ratio of the polymer in the polymer solution and the polyphenol in the polyphenol solution in the step (2) is (1-3):
1.
5. The preparation method according to claim 1, characterized in that: The temperature of the dehydration condensation reaction in the step (2) is 4 to 40° C., and the time of the dehydration condensation reaction is 1 to 48 hours.
6. The preparation method according to claim 1, characterized in that: The molar ratio of the polyphenols in the polyphenol solution of step (2) to the metal ions in the metal salt solution of step (3) is (0.5-10):
1.
7. The preparation method according to claim 1, characterized in that: In the step (3), the molar ratio of calcium peroxide in the drug-loaded calcium peroxide nanoparticles to metal ions in the metal salt solution is (20-50):
1.
8. The preparation method according to claim 1, characterized in that: The temperature of the coordination complex reaction in step (3) is 4 to 40° C., and the time of the coordination complex reaction is 1 to 48 hours.
9. The metal polyphenol network-coated calcium peroxide nanoparticles prepared by the preparation method according to any one of claims 1 to 8, comprising drug-loaded calcium peroxide nanoparticles and the metal polyphenol network coated on the surface of the drug-loaded calcium peroxide nanoparticles.
10. Use of the metal polyphenol network-encapsulated calcium peroxide nanoparticles according to claim 9 in the preparation of tumor drugs.
Citation Information
Patent Citations
Preparation method of multi-channel Ca < 2 + > nano regulator for promoting tumor calcium overload
CN116440078A
Nanoparticles based on calcium peroxide and manganese dioxide as well as preparation method and application of nanoparticles
CN117257985A
Cited By
Application of protein complex in preparation of hypoglycemic drugs
CN120285210A
Multi-active metal-polyphenol network-protein compound, medicine and application
CN120305416A
Drug-loaded nanoparticle and metal polyphenol network mediated food-borne assembly
CN120381531A
Method for reducing allergenicity of separated whey protein and application
CN120549156A
Self-oxygen-producing nano composite particle as well as preparation method and application thereof
CN120754045A
